GATA binding protein 4 (GATA4) is a pioneer transcription factor critical for cardiac development, cardiomyocyte survival, and cellular senescence. As a master regulator, GATA4 orchestrates gene expression networks by binding to conserved WGATAR genomic motifs. In therapeutic development, GATA4 is actively targeted for cardiac regenerative medicine (direct reprogramming), cellular senescence (SASP pathway modulation), and specific oncology indications where GATA4 acts as a lineage-survival oncogene. Validating therapeutics targeting GATA4 requires highly specific reagents that can overcome the challenges of transcription factor delivery, nuclear localization, and family-wide homology.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GATA4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GATA4 Recombinant Protein (Full-Length & Zinc Finger Domain) High purity (>90%), Endotoxin Controlled. Sequence Verified. Suitable for DNA-binding assays. |
View GATA4 Products |
| Gene Delivery | GATA4 Promise-ORF / Lentivirus Full-length human GATA4 ORF for stable cell line generation and cardiac reprogramming assays. |
View GATA4 Products |
| Benchmark Ab | Anti-GATA4 Recombinant Antibody High-affinity sequence-verified clone for chromatin immunoprecipitation (ChIP), Western Blot, and IHC controls. |
View GATA4 Products |
| Validator | GATA4 siRNA Set Target-specific knockdown pool for functional verification in primary cardiomyocytes or senescent cells. |
View GATA4 Products |
| Related Target A | NKX2-5 Essential cardiac transcription factor that synergizes physically and functionally with GATA4 during cardiogenesis. |
View NKX2-5 Products |
| Related Target B | TBX5 Core component of the GMT (GATA4/MEF2C/TBX5) reprogramming cocktail used to convert fibroblasts into functional cardiomyocytes. |
View TBX5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GATA Family Off-Target Cross-Reactivity | GATA family panel proteins (GATA1, GATA2, GATA3, GATA5, GATA6) strictly verified by mass spectrometry to ensure assay selectivity. |
| Low Yield & Instability of Nuclear Proteins | E. coli & Insect cell expression platforms optimized for zinc-finger stability, using native-like buffer formulations to prevent aggregation. |
| Lack of Controls | Recombinant Benchmark Antibodies and validated positive control plasmids included in the catalog. |
| False Positives in Knockdown Studies | Sequence-verified siRNA pools with non-targeting negative controls for high-confidence phenotypic validation. |
Live GATA4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of GATA4 is undergoing a paradigm shift. Historically classified as "undruggable" due to its intracellular localization and lack of a traditional small-molecule binding pocket, GATA4 is now at the forefront of two major clinical frontiers: cardiac regeneration and senolytic therapy. In regenerative medicine, researchers are utilizing viral vectors (adenovirus or lentivirus) delivering GATA4 in combination with TBX5 and MEF2C to drive in vivo transdifferentiation of cardiac fibroblasts into functional cardiomyocytes. Concurrently, in the field of aging and senology, GATA4 has been identified as a key regulator of the Senescence-Associated Secretory Phenotype (SASP). Small molecules disrupting GATA4 stabilization or promoting its selective degradation (via PROTAC technology) represent a novel class of senolytics targeting chronic inflammatory diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy / RNA | Tenaya Therapeutics, Academic Medical Centers | Heart Failure, Myocardial Infarction | High-titer, sequence-verified Lentivirus / Adenovirus constructs for robust in vitro reprogramming efficiency assays. |
| Small Molecule (PPI Inhibitors) | Biotech Startups, Senolytic Consortia | Idiopathic Pulmonary Fibrosis, Age-related Degeneration | High-purity recombinant GATA4 and NKX2-5 proteins to establish robust protein-protein interaction (PPI) screening assays (e.g., AlphaLISA). |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | SASP-driven Inflammatory Disorders, Ovarian Cancer | Native-state recombinant proteins and high-affinity antibodies for Western Blot and cellular degradation kinetic assays. |